eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on translation control therapies targeting the eIF4F complex in oncology, which went public through a business combination with Locust Walk Acquisition Corp., a blank-check company sponsored by Locust Walk Partners that completed its IPO in 2020. On October 1, 2021, eFFECTOR filed an amended registration statement on Form S-1/A with the SEC, accession number 0001193125-21-289863, as part of the de-SPAC registration process. Following the transaction close, the combined company traded on Nasdaq under the ticker EFTR, operating within the life sciences and precision oncology sector. Sign up for full data on SpacDesk to access complete filing histories, sponsor profiles, and deal intelligence across the SPAC market.